Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$585.4m

Candel Therapeutics Past Earnings Performance

Past criteria checks 0/6

Candel Therapeutics's earnings have been declining at an average annual rate of -8.6%, while the Biotechs industry saw earnings growing at 33.8% annually. Revenues have been declining at an average rate of 62% per year.

Key information

-8.64%

Earnings growth rate

18.79%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-62.02%
Return on equity-39.43%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Apr 21

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Summary Candel Therapeutics, Inc. seems positioned for significant upside as its lead asset, aglatimagene, nears key prostate cancer Phase 3 readouts and a potential BLA filing. CADL's aglatimagene has demonstrated statistically significant improvements in disease-free survival and safety, supporting a strong case for FDA approval and commercial launch in 2027. Recent analyst price targets ($26–$30) and market excitement reflect confidence in CADL's late-stage pipeline, especially given the $2.9bn peak revenue estimate for aglatimagene. CADL’s robust cash position funds operations into Q1 2028, but commercial execution and payer adoption remain critical risks to monitor post-approval. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Candel Therapeutics: Entering Its Pivotal Year

Summary Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action. Big risks remain due to its negative EPS and debt ratios, but that potential FDA approval and its varied proprietary platforms make Candel an attractive acquisition target. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Summary Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025. Viral therapies like CAN-2409 face commercialization challenges, but the strong phase 3 data justifies maintaining a "Buy" rating for CADL stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 01

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Summary Candel Therapeutics develops biological immunotherapies, combining anti-tumor and immune-stimulatory elements to target and destroy cancer cells. Its leading candidates, CAN-2409 and CAN-3110, show promising results in clinical trials for various cancers. CAN-2409 received multiple FDA designations, including Fast Track, Special Protocol Assessment, and Orphan Drug designation for pancreatic cancer. Unfortunately, CADL has significant financial questions, with a high cash burn rate and a short runway, which will necessitate additional funding soon, in my opinion. The company’s need to raise funds, likely through equity, may result in substantial stock dilution, leading to a "sell" rating despite promising IP. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Summary Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024. Data readouts from two other studies expected in Q4 of 2024, both of which deal with the targeting of patients with localized prostate cancer using CAN-2409. Read the full article on Seeking Alpha
Seeking Alpha • Sep 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics (NASDAQ:CADL) on Thursday said a European drug regulator committee had given a positive recommendation to grant an orphan drug designation to the company's CAN-2409 therapy for the treatment of glioma, which is a type of tumor that occurs in the brain and spinal cord. The European Medicines Agency's (EMA) Committee for Orphan Medical Products issued the positive opinion, CADL said in a statement. CAN-2409 is a genetically modified adenovirus that is currently being evaluated in multiple phase 2 and 3 trials for lung, brain, pancreatic and prostate cancers, CADL said. The EMA's orphan designation is given to medicines developed for rare, life-threatening diseases. CADL said the orphan drug designation follows a U.S. FDA fast track designation granted in June last year for CAN-2409 to be used in combination with antiviral drug valacyclovir to treat newly diagnosed glioma. CADL stock +3.7% to $3.64 in early trading.
Seeking Alpha • Sep 07

Candel Therapeutics appoints CFO, chief medical officer

Biopharmaceutical company Candel Therapeutics (NASDAQ:CADL) appointed Jason Amello CFO and Garrett Nichols chief medical officer. Amello, whose appointment is effective Sep. 21, is replacing John Canepa. Canepa has decided to pursue other interests and spend more time with his family. Amello joins from the rare disease biotech company Saniona, while Nichols joins from Istari Oncology. Source: Press Release
Seeking Alpha • Oct 21

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Candel is an immunotherapy company with a lead asset, CAN-2409, in Phase 3 clinical trials for prostate cancer. CAN-2409 has a strong clinical safety data across >700 patients and the potential to become a transformative therapy in prostate cancer. With ongoing pivotal clinical trials across 2 stages of prostate cancer along with trials in glioma and NSCLC, CAN-2409 will serve as a key catalyst for Candel. Depending on the binary event of the lead clinical trial, Candel Therapeutics will be in a position to expand CAN-2409’s use for more indications, expand the platform, and engage in more partnerships.

Revenue & Expenses Breakdown

How Candel Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:CADL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-542136
31 Dec 250-381830
30 Sep 250-231723
30 Jun 250-221520
31 Mar 250-401519
31 Dec 240-551519
30 Sep 240-521438
30 Jun 240-501432
31 Mar 240-371427
31 Dec 230-381424
30 Sep 230-32140
30 Jun 230-32150
31 Mar 230-27150
31 Dec 220-19150
30 Sep 220-12160
30 Jun 220-20150
31 Mar 220-33130
31 Dec 210-36110
30 Sep 210-48103
30 Jun 210-3588
31 Mar 210-2078
31 Dec 200-1868
31 Dec 190-830

Quality Earnings: CADL is currently unprofitable.

Growing Profit Margin: CADL is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CADL is unprofitable, and losses have increased over the past 5 years at a rate of 8.6% per year.

Accelerating Growth: Unable to compare CADL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CADL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43%).

Return on Equity

High ROE: CADL has a negative Return on Equity (-39.43%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 09:54
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Candel Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Alec StranahanBofA Global Research
Brian Kemp DolliverBrookline Capital Markets